GRI Bio, Inc. (NASDAQ:GRI – Get Free Report) was the target of a significant decrease in short interest in the month of August. As of August 15th, there was short interest totalling 2,800 shares, a decrease of 96.6% from the July 31st total of 83,400 shares. Based on an average trading volume of 495,800 shares, the days-to-cover ratio is currently 0.0 days. Approximately 0.1% of the company’s shares are short sold.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in GRI Bio stock. Armistice Capital LLC acquired a new stake in GRI Bio, Inc. (NASDAQ:GRI – Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 50,207 shares of the company’s stock, valued at approximately $96,000. Armistice Capital LLC owned 9.23% of GRI Bio at the end of the most recent quarter. Hedge funds and other institutional investors own 33.95% of the company’s stock.
GRI Bio Stock Performance
GRI Bio stock traded up 0.07 during mid-day trading on Tuesday, hitting 0.58. The company’s stock had a trading volume of 950,536 shares, compared to its average volume of 227,415. GRI Bio has a one year low of 0.40 and a one year high of 188.37. The company has a 50 day moving average of 1.33 and a 200-day moving average of 5.48.
About GRI Bio
GRI Bio, Inc, a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development.
Further Reading
- Five stocks we like better than GRI Bio
- Insider Trading – What You Need to Know
- Study: How Much Are Retirees Earning from Side Hustles in 2024?
- The Role Economic Reports Play in a Successful Investment Strategy
- Brinker International Offers a Pullback Opportunity on EPS Miss
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- Globant Is an Emerging AI Play That’s Expanding Its Footprint
Receive News & Ratings for GRI Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GRI Bio and related companies with MarketBeat.com's FREE daily email newsletter.